Sign In
Buy MRK
$120.78
+1.69 (+1.41%)
At Close: Jun 11, 2026
CPC Advisors LLC Increases Position in Merck & Co., Inc. $MRK
04:44am, Wednesday, 22'nd Apr 2026
CPC Advisors LLC grew its holdings in Merck and Co., Inc. (NYSE: MRK) by 1,728.8% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 68,380 shares of the compa
Why Dow Jones Stock Merck Skidded 4% — And Boosted A Key Rival
02:14pm, Tuesday, 21'st Apr 2026
Merck stock skidded Tuesday — while also buoying Exelixis — after the Dow Jones pharma outlet said a triple approach to kidney cancer failed.
FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir)
02:11pm, Tuesday, 21'st Apr 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved IDVYNSO�
MRK's sBLAs for Keytruda Combo in Bladder Cancer Get FDA Priority Tag
01:01pm, Tuesday, 21'st Apr 2026
FDA grants priority review to Merck's sBLAs for Keytruda & Keytruda SC in combination with Pfizer's Padcev in cisplatin-eligible MIBC patients.
US FDA approves Merck's combination HIV treatment
11:53am, Tuesday, 21'st Apr 2026
The U.S. Food and Drug Administration approved Merck's once-daily, oral, combination regimen for HIV infections, the health regulator's website showed on Tues
Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock?
09:56am, Tuesday, 21'st Apr 2026
Merck stock up 11% YTD as Keytruda growth, pipeline gains and M&A lift outlook, but patent risks, Gardasil slump and generics weigh on near-term upside.
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
06:53am, Tuesday, 21'st Apr 2026
Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on �
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advance
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:51pm, Monday, 20'th Apr 2026
In the closing of the recent trading day, Merck (MRK) stood at $117.1, denoting a -1.65% move from the preceding trading day.
Merck Secures EU Nod for RSV Antibody Enflonsia in Infants
10:07am, Monday, 20'th Apr 2026
MRK gains EU approval for Enflonsia to prevent RSV in infants during their first season.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) granted priority review for two
Birch Hill Investment Advisors LLC Sells 4,923 Shares of Merck & Co., Inc. $MRK
03:43am, Sunday, 19'th Apr 2026
Birch Hill Investment Advisors LLC lessened its position in Merck and Co., Inc. (NYSE: MRK) by 5.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities an
Better Pharma Dividend Stock: Novartis vs. Merck
02:37pm, Friday, 17'th Apr 2026
Merck's outlook is bright despite challenges to its core franchises. Novartis is performing well despite a recent major patent cliff.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck press release announcing European Commission approval of ENFLONSIA.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Thursday, 16'th Apr 2026
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
